UCB's Global Corporate Website
Welcome to UCB in the United States


Find U.S. news and updates from UCB, a global biopharmaceutical company focused on creating value for people living with severe diseases, such as epilepsy, Parkinson’s disease, psoriasis, osteoporosis, myasthenia gravis,  rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, and more. 

Spotlight Story

No results



UCB U.S. News

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-…

Read More

Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral…

Read More

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Read More

Twitter Feed

For More Information